v3.26.3
Organization and Basis of Presentation - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 23, 2026
Jun. 22, 2026
Apr. 01, 2025
Apr. 02, 2024
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Line Items]                        
Entity Incorporation, State or Country Code                 DE      
Net proceeds                       $ 93,000,000
Common stock, shares authorized       700,000,000 700,000,000       700,000,000   700,000,000 700,000,000
Preferred stock, shares authorized       70,000,000 70,000,000       70,000,000   70,000,000 70,000,000
Preferred stock, par value       $ 0.0001 $ 0.0001       $ 0.0001   $ 0.0001 $ 0.0001
Common stock, par value       $ 0.0001 $ 0.0001       $ 0.0001   $ 0.0001 $ 0.0001
Aggregate offering price of common stock         $ 2,000       $ 2,000   $ 2,000 $ 2,000
Cash, cash equivalents, and short-term investments         72,600,000       72,600,000   107,600,000  
Accumulated deficit         (296,917,000)       (296,917,000)   (259,669,000) (201,472,000)
Net loss         (23,693,000) $ (13,555,000) $ (15,675,000) $ (15,758,000) (37,248,000) $ (31,433,000) (58,197,000) (65,363,000)
Net cash used in cash flows from operations                 $ (35,945,000) $ (26,359,000) (46,661,000) $ (60,841,000)
Lease Termination Effective Date                 May 31, 2026      
Payments to landlord on lease termination         (10,000,000)       $ (10,000,000)      
Security Deposit         $ 500       $ 500      
Serapha Bio Inc [Member] | Merger Agreement [Member]                        
Organization, Consolidation and Presentation of Financial Statements [Line Items]                        
Business Combination, Voting Equity Interest Acquired, Percentage         96.20%       96.20%      
Percentage Of Common Stock Owned After Merger   3.80%                    
Proceeds from Issuance of Common Stock   $ 200,000,000                    
Termination Fee Amount Payable By Terminating Party   $ 1,000,000                    
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent 75.00%                      
Restructuring Charges                 $ 2,800,000      
Accrued Compensation Liability         $ 2,800,000       2,800,000   $ 0  
Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense | Serapha Bio Inc [Member] | Merger Agreement [Member]                        
Organization, Consolidation and Presentation of Financial Statements [Line Items]                        
Restructuring Charges         1,300,000              
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | Serapha Bio Inc [Member] | Merger Agreement [Member]                        
Organization, Consolidation and Presentation of Financial Statements [Line Items]                        
Restructuring Charges         1,500,000              
Maximum | Serapha Bio Inc [Member] | Merger Agreement [Member]                        
Organization, Consolidation and Presentation of Financial Statements [Line Items]                        
Restructuring and Related Cost, Expected Cost Remaining         5,000,000       5,000,000      
Minimum [Member] | Serapha Bio Inc [Member] | Merger Agreement [Member]                        
Organization, Consolidation and Presentation of Financial Statements [Line Items]                        
Restructuring and Related Cost, Expected Cost Remaining         $ 3,000,000       $ 3,000,000      
IPO                        
Organization, Consolidation and Presentation of Financial Statements [Line Items]                        
Shares sold       6,250,000                
Share price       $ 16                
Net proceeds       $ 87,700,000                
Convertible preferred stock converted into common stock       14,740,840                
Open Market Sale Agreement                        
Organization, Consolidation and Presentation of Financial Statements [Line Items]                        
Shares sold                 0   0  
Open Market Sale Agreement | Maximum                        
Organization, Consolidation and Presentation of Financial Statements [Line Items]                        
Percentage of agent commission on gross proceeds of common stock sold     3.00%                  
Aggregate offering price of common stock     $ 14,500,000